Access to this content is restricted
Learning objectives
- Understand how to integrate liquid biopsy in clinical trials for breast cancer patients in terms of concepts of patient identification to surrogates of standard endpoints
- Understand the use of liquid biopsy profiling in breast cancer for prognosis, biomarker discovery and patient stratification
- Understand the use of liquid biopsy dynamics to capture tumour evolution and drug resistance in breast cancer
This webinar aims to review and discuss data for liquid biopsy-based assessments as endpoints of antitumour activity in clinical trials, understand the potential and limitations of liquid biopsy-based tumour genomic profiling for patient stratification and detection of predictive biomarkers of response to therapy, and to discuss how tumour heterogeneity and evolution assessed via liquid biopsy assays may improve breast cancer treatment strategies.